Cyrus Biotechnology is a pre-clinical-stage biotech company combining protein design and screening to create novel biologics for serious unmet medical needs. Using this approach, we are developing an early pipeline of innovative programs in multiple indications. We are also partnering with leading biotech and pharma companies and research institutes to bring collaborative programs forward from discovery to the clinic.
Cyrus is based on core software from the lab of David Baker at the University of Washington. Weve worked with over 90 industry partners. We are based in Seattle, WA and financed by leading US and Asian Biotech and Tech investors including Orbimed, Trinity Ventures, Springrock, Agent Capital, iSelect, Yard Ventures, WRF and Alexandria.
